Indeed, the vast majority of GEMMs developed through genetic alterations in estrogen signaling molecules or oncogenes has been reported to predominantly yield mammary tumors that are HR− or lose ER expression when exposed to endocrine therapy [52–54]. The gene discussed is ESR1; the disease is breast cancer.